St Vincent's Nelune Men's Health Centre
DONATE NOW

Theranostics

Home / Treatments / Theranostics

Learn about theranostics – a combination of therapy and diagnostics – as a treatment for prostate cancer.

What is theranostics for prostate cancer?

Theranostics is a highly precise treatment that aims to treat prostate cancer by combining therapy and diagnostic tools (hence the term, ‘theranostics’). It’s a relatively new cancer treatment, and it has had most success in treating metastatic prostate cancer and neuroendocrine tumours.

Theranostics comprises two steps:

  • a PET-CT scan – a highly specific scan to determine whether targets called tumour receptors are present on prostate cancer cells
  • an injection of PSMA-targeted radionuclide therapy – an internalised radiation treatment that selectively targets the tumour cells but avoids damaging healthy cells.

The theranostic treatment for prostate cancer is called lutetium PSMA therapy (or ‘lutetium PSMA’). Lutetium-177 is a radioactive element that damages and destroys prostate cancer cells. PSMA (which stands for ‘prostate-specific membrane antigen’) is a type of protein found on the surface of cells in the prostate gland, some tumours and normal tissues.

Lutetium PSMA therapy doesn’t cure prostate cancer, but it can help people to have a long period of remission and has been shown to improve survival. It aims to:

  • improve your symptoms
  • reduce the size of your tumours
  • slow the growth of your tumours.

Below, you can watch a short animation that explains theranostics.

What does theranostics for prostate cancer involve?

Prostate cancer cells express around 1,000 times the amount of PSMA that normal prostate cells express. The PET-CT scan can show where PSMA avid tissue in other parts of the body when the cancer has spread. This is the diagnostic part of your theranostic treatment.

Then, you will have lutetium PSMA therapy:

  • Lutetium-177 is bound to a PSMA peptide.
  • The PSMA peptide transports the lutetium-177 directly to the tumour site.
  • The lutetium-177 damages and destroys prostate cancer cells in a targeted way.

As a result, the rest of your body is exposed to less radiation.

This video explains more about the role of PSMA in prostate cancer treatment.

Is theranostics suitable for me?

Theranostics may be appropriate for treating people with prostate cancers that:

  • have spread (metastasised)
  • are advanced
  • haven’t responded to other treatments.

Theranostics may also be an option if other treatments are causing you significant harm or side effects.

Theranostics illustration

What are the side effects of theranostics for prostate cancer?

Like all cancer treatments, there may be side effects associated with lutetium PSMA therapy, including:

  • dry mouth
  • tiredness
  • mild nausea
  • loss of appetite
  • reduced production of blood cells.

Most of the radioactive drug that doesn’t reach the target is quickly passed out of the body, so these side effects should only be temporary. You’ll have regular blood tests to monitor your health status during and after your treatment.

If you’ve already had cancer treatments, like chemotherapy and radiotherapy, your bone marrow may be more sensitive to the radiation. If you have any questions or concerns about side effects, speak to your specialist.

Website Feedback Survey

We welcome and need your feedback in order to improve the quality of our service. Please take a few minutes to complete our survey
Take part in survey
St Vincent's Curran Foundation
Donate today to the St Vincent’s NELUNE Men’s Health Centre to help St Vincent's Hospital Sydney stay at the forefront of prostate cancer care and research.
DONATE NOW
crossmenu